News

Art Mandell Departs from MaxCyte Board and Legacy Continues

Art Mandell Departs from MaxCyte Board and Legacy Continues

Art Mandell's Departure from MaxCyte Board

MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a pioneering company in cell engineering dedicated to advancing cell therapeutics, has announced the retirement of board member Art Mandell. His retirement will take effect on December 31, 2024. Mandell has been an integral part of MaxCyte's board since 2006, contributing significantly to the company’s journey, particularly during its public offerings on both the UK AIM exchange and the US Nasdaq, as well as the development of its innovative ExPERT™ platform.

Contributions to the Cell Engineering Sector

The leadership of Art Mandell at MaxCyte has proved invaluable for the growth and positioning of the company in the competitive field of cell engineering. The board's chairman, Richard Douglas, expressed deep appreciation for Mandell’s profound insights and notable contributions throughout his tenure. Mandell has articulated his pride in the evolution of MaxCyte and has expressed confidence in the company’s ongoing endeavors, particularly in offering groundbreaking solutions in the realm of cell and gene therapies.

Understanding the ExPERT™ Platform

MaxCyte’s ExPERT™ platform stands out in the market for its robust support across the lifecycle of cell therapy development, ranging from initial discovery to full commercialization. This powerful platform is equipped with a variety of instruments, proprietary disposables, and comprehensive software protocols. Furthermore, it is supported by an extensive intellectual property portfolio that adds to its strength and reliability.

Looking Ahead Post-Retirement

While the specifics regarding Mandell’s successor or potential shifts in the board's structure following his retirement remain under wraps, MaxCyte’s commitment to the advancement of cell-based medicines is unwavering. The company continues to forge ahead with strategic platform licenses and is actively involved in supporting the pioneering efforts of the industry’s first FDA-approved non-viral cell therapy, which utilizes CRISPR technology.

Frequently Asked Questions

Why did Art Mandell retire from MaxCyte's board?

Art Mandell retired to reflect on his lengthy tenure and to allow new leadership to guide MaxCyte's future.

What impact did Mandell have on MaxCyte?

Mandell played a significant role in MaxCyte’s growth, especially during its IPO and the development of the ExPERT™ platform.

What is the ExPERT™ platform?

The ExPERT™ platform is a comprehensive system designed to support cell therapy development from discovery through commercialization.

What are MaxCyte’s future goals?

MaxCyte aims to continue advancing cell-based medicines and supporting innovative therapies such as CRISPR edited therapies.

Who will succeed Art Mandell on the board?

As of now, MaxCyte has not disclosed information regarding Mandell's successor on the board of directors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Knob-and-Tube Wiring: A Hidden Hazard Unveiled

Updated Category News Views 99

Unlocking the Mysteries of Knob-and-Tube Wiring Ever wondered if the wiring in your charming hundred-year-old home might be a ticking time bomb? Welcome to the world of knob-and-tube wiring. This blast from the past might just be hiding in those walls and could spell trouble. The History and Hazards of Knob-and-Tube This wiring system dates back to the 1880s, sticking...

Continue Reading
UPM-Kymmene Finalizes Demerger: WISA Group to Nasdaq

Updated Category News Views 94

UPM-Kymmene Shakes Things Up Here's the meat and potatoes: UPM-Kymmene Corporation is going through a big change. They've decided to cut a part of themselves off and send it out into the world. This partial demerger has been registered, and now WISA Group Plc is stepping out from UPM's shadow. Where to? They're headed for the big league, getting listed on Nasdaq Helsinki....

Continue Reading
Mastering Progressive Overload: Break Workout Plateaus

Updated Category News Views 143

Getting off the Fitness Merry-Go-Round You've been hitting the gym, feeling great, and suddenly—bam! You've hit a wall so hard you might as well be a bug on a windshield. That's where our buddy Joshua Bankes comes in, explaining the magic of progressive overload for fitness buffs. Understanding Plateau Phenomena Remember, results aren't linear. As you start a new...

Continue Reading
TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Updated Category News Views 224

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Continue Reading
Tenax Therapeutics Faces Class Action Amid Massive Loss

Updated Category News Views 172

Investors Eye Deadline Amidst Legal Storm Holy moly, Tenax Therapeutics is caught with their pants down—and we're not talking loose change. Any sorry soul who bought into Tenax's promises about their TNX-103 drug is now staring down a high-stakes class action lawsuit. If you were holding on to those dreams turned nightmares between November 13, 2023, and August 7, 2026,...

Continue Reading
AI-Powered Bank Set to Transform Bahrain's Financial Landscape

Updated Category News Views 127

A Fresh Approach to Banking in Bahrain The stuff that's stirring the pot in Bahrain’s financial sector right now? This big ol' partnership between Mumtalakat, the Kingdom's sovereign wealth fund, and ARP Group. They're on a mission to launch an AI-native wholesale bank smack dab in Bahrain. But here’s the kicker – they’ve got the green light, in principle at...

Continue Reading
Double Down for Veterans Raises $20 Million Goal

Updated Category News Views 152

Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...

Continue Reading
CPC's Rigorous Self-Governance Balances Power Effectively

Updated Category News Views 196

What's the Deal With Those Ancient Quotes? There's nothing like a quote from the Warring States Period to set the stage for good ol' fashioned governance chatter. Lu Buwei's words about rulers and compass points is historic, sure, but it speaks to the core need for standards in today's China. This isn't just some fortune cookie wisdom; it's a clarion call for order and...

Continue Reading
Virtual K-Pop Takes U.S. by Storm: HYPEVERSE Emerges

Updated Category News Views 135

The Rise of Virtual K-Pop Across the Atlantic It's a bold new world for K-pop, and HYPEVERSE is leading the charge. Forget the typical idol group—this one's pulling out all the stops by going virtual and zeroing in on American audiences. Now, as someone who's been burned by the volatility of music stocks in the past, I'm peering at this development with a mix of...

Continue Reading
Investcorp's Strong 2026: A Deep Dive into Key Moves

Updated Category News Views 27

Diving into Investcorp's Robust 2026 Performance If you're clued into the investment scene, you'll know that a $65.2 billion asset base isn't small potatoes. At the Gateway Gulf 2026, Investcorp didn't just present numbers—they laid out a dramatic year of action packed with billion-dollar dreams. While the dust hasn't quite settled yet, the first nine months of the year...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding SoFi Technologies Stock's Recent Decline

Updated Category News Views 373

SoFi Technologies Stock Experiences a Setback SoFi Technologies Inc (NASDAQ: SOFI) has seen its shares decline recently, following the announcement of a public offering of common stock. Understanding the implications of such moves is essential for investors and stakeholders. Key Developments Behind the Decline The driving force behind the dip in SoFi's stock price is the...

Continue Reading
CXM Investors: Your Guide to Participating in Shareholder Rights

Updated Category News Views 76

Understanding the Sprinklr, Inc. Lawsuit The Schall Law Firm is reaching out to investors regarding a class action lawsuit against Sprinklr, Inc. (CXM). This alert serves to inform those who may have experienced losses due to recent misleading public statements made by the company. Who Is Affected by the Lawsuit? Investors who purchased securities of Sprinklr within a...

Continue Reading
Children's Hospital of Philadelphia Achieves Duchenne Care Certification

Updated Category News Views 188

Celebrating a Landmark Achievement in Duchenne Care Parent Project Muscular Dystrophy (PPMD), a leading nonprofit organization dedicated to the fight against Duchenne muscular dystrophy, has announced a significant milestone in clinical care for this devastating genetic disorder. The Children's Hospital of Philadelphia (CHOP) has received certification as a Certified...

Continue Reading
Diamond Antenna Expands Horizons with Strategic Acquisition

Updated Category News Views 286

Diamond Antenna's Strategic Move: Acquiring Antenna Associates Diamond Antenna and Microwave Corporation has taken a significant step by acquiring Antenna Associates, Inc. This acquisition marks a crucial chapter in Diamond's journey, expanding its capabilities within the realm of advanced radio frequency (RF) and electro-mechanical solutions. Enhancing Product Offerings...

Continue Reading
Celsius Holdings Faced with Securities Lawsuit: Learn Your Rights

Updated Category News Views 283

Understanding the Recent Legal Challenge Facing Celsius Holdings, Inc. Celsius Holdings, Inc. finds itself at the center of a significant legal battle. This lawsuit raises serious allegations regarding securities law violations. For shareholders of Celsius, also known under the stock ticker CELH, this development is critical, especially for those who made purchases within...

Continue Reading